undefined
EUTM file information

018665892

BEXIGNUS


March 1, 2022

Trademark Summary

The trademark application BEXIGNUS was filed by Faron Pharmaceuticals Oy, a corporation established under the laws of the Republic of Finland (the "Applicant"). The application was published for oppositions on March 14, 2022, and it was registered by office on June 21, 2022 without any oppositions.

It was designated 'Basic Application' for International Application 1684033 at the World Intellectual Property Organization (WIPO).

The application was filed in Finnish (English was selected as the second language).


Goods And Services

  • The mark was filed in class 5 with following description of goods:
    1. Pharmaceuticals
    2. Medical preparations
    3. Veterinary preparations
    4. Sanitary preparations for medical purposes
    5. Pharmaceutical preparations and substances for the treatment of cancer
    6. Tumor suppressing agents
    7. Antineoplastics
    8. Anti-cancer preparations
    9. Compounds for treating cancer
    10. Antibodies
    11. Biological preparations for medical purposes
    12. Adjuvants for medical purposes
    13. Vaccine adjuvants
    14. Anti-neoplastic preparations of chemical origin
    15. Anti-neoplastic preparations of microbial origin
    16. Antigens
    17. Biological preparations for the treatment of cancer
    18. Biopharmaceuticals for the treatment of cancer
    19. Biotechnological preparations for medical use
    20. Immunomodulators
    21. Pharmaceutical preparations for the treatment of immune system related diseases and disorders
    22. Pharmaceutical preparations and substances for use in oncology
    23. Pharmaceutical preparations for the prevention of disorders of the immune system
    24. Serotherapeutic medicines
    25. Pharmaceutical preparations for immunity adjustment
    26. Pharmaceutical preparations for regulating the immune system
    27. Pharmaceutical preparations for the treatment of autoimmune diseases
    28. Pharmaceutical preparations for use in hematology.